"Dosing the first patient in our Phase 1/2 trial of NEO-811 in renal cell carcinoma marks a pivotal inflection point for Neomorph, representing the first clinical evaluation of an asset from our ...
AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.
In a groundbreaking development for cancer treatment, Neomorph, a local biotech firm, has begun clinical trials for its innovative molecular glue, NEO-811. This nove ...
This local biotech says it has found a way to trick cancer cells into destroying themselves with its molecular glue. Now it’s putting that claim to the test. After attracting global attention from ...
The first patient dosing in the Phase 1/2 trial represents a crucial step in assessing NEO-811's efficacy and safety. The Phase 1/2 NEO-811-101 trial is a first-in-human, open-label study designed to ...
SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc. announced a $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs. Deerfield Management ...
AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based private biotech Neomorph to develop molecular glue degraders for multiple ...
Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. AbbVie will pay ...
Please provide your email address to receive an email when new articles are posted on . Biogen Inc. and Neomorph Inc. have announced a partnership geared toward research and development of molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results